Mary J. Tevethia All publications ( 28 ) Dhamne C. Drubin DA. Duncan K. Tevethia MJ. Clawson GA. The chloromethylketone protease inhibitor AAPF(CMK) also targets ATP-dependent helicases and SAP-domain proteins. 2007 Feb 15. J Cell Biochem. 100(3):716-26. Bollag B. Kilpatrick LH. Tyagarajan SK. Tevethia MJ. Frisque RJ. JC virus T'135, T'136 and T'165 proteins interact with cellular p107 and p130 in vivo and influence viral transformation potential. 2006 Dec. J Neurovirol. 12(6):428-42. National Cancer Institute National Institute of Neurological Disorders and Stroke Otahal P. Hutchinson SC. Mylin LM. Tevethia MJ. Tevethia SS. Schell TD. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. 2005 Jul 15. J Immunol. 175(2):700-12. National Cancer Institute Staveley-O'Carroll K. Schell TD. Jimenez M. Mylin LM. Tevethia MJ. Schoenberger SP. Tevethia SS. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. 2003 Jul 15. J Immunol. 171(2):697-707. National Cancer Institute Cole SL. Tevethia MJ. Simian virus 40 large T antigen and two independent T-antigen segments sensitize cells to apoptosis following genotoxic damage. 2002 Aug. J Virol. 76(16):8420-32. National Cancer Institute Beachy TM. Cole SL. Cavender JF. Tevethia MJ. Regions and activities of simian virus 40 T antigen that cooperate with an activated ras oncogene in transforming primary rat embryo fibroblasts. 2002 Apr. J Virol. 76(7):3145-57. National Cancer Institute Tevethia S. Beachy T. Schell T. Lippolis J. Newmaster R. Mylin L. Tevethia MJ. Role of CTL host responses and their implication for tumorigenicity testing and the use of tumour cells as vaccine substrate. 2001. Dev Biol (Basel). 106:109-21; discussion 143-60. National Cancer Institute Tevethia MJ. Ozer HL. SV40-mediated immortalization. 2001. Methods Mol Biol. 165:185-99. National Institute on Aging National Cancer Institute Tevethia MJ. Lacko HA. Conn A. Two regions of simian virus 40 large T-antigen independently extend the life span of primary C57BL/6 mouse embryo fibroblasts and cooperate in immortalization. 1998 Apr 10. Virology. 243(2):303-12. National Cancer Institute Tevethia SS. Mylin L. Newmaster R. Epler M. Lednicky JA. Butel JS. Tevethia MJ. Cytotoxic T lymphocyte recognition sequences as markers for distinguishing among tumour antigens encoded by SV40, BKV and JCV. 1998. Dev Biol Stand. 94:329-39. National Cancer Institute Tevethia MJ. Bonneau RH. Griffith JW. Mylin L. A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice. 1997 Nov. J Virol. 71(11):8157-66. National Cancer Institute Tevethia MJ. Lacko HA. Kierstead TD. Thompson DL. Adding an Rb-binding site to an N-terminally truncated simian virus 40 T antigen restores growth to high cell density, and the T common region in trans provides anchorage-independent growth and rapid growth in low serum concentrations. 1997 Mar. J Virol. 71(3):1888-96. National Cancer Institute Fu TM. Bonneau RH. Epler M. Tevethia MJ. Alam S. Verner K. Tevethia SS. Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein. 1996 Aug 1. Virology. 222(1):269-74. National Institute of Allergy and Infectious Diseases National Cancer Institute Cavender JF. Conn A. Epler M. Lacko H. Tevethia MJ. Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts. 1995 Feb. J Virol. 69(2):923-34. National Cancer Institute Rajan P. Swaminathan S. Zhu J. Cole CN. Barber G. Tevethia MJ. Thimmapaya B. A novel translational regulation function for the simian virus 40 large-T antigen gene. 1995 Feb. J Virol. 69(2):785-95. National Institute of Allergy and Infectious Diseases National Cancer Institute Mylin LM. Deckhut AM. Bonneau RH. Kierstead TD. Tevethia MJ. Simmons DT. Tevethi SS. Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen. 1995 Apr 1. Virology. 208(1):159-72. National Cancer Institute Spector DJ. Tevethia MJ. Protein-protein interactions between human cytomegalovirus IE2-580aa and pUL84 in lytically infected cells. 1994 Nov. J Virol. 68(11):7549-53. National Cancer Institute National Center for Research Resources Samaniego LA. Tevethia MJ. Spector DJ. The human cytomegalovirus 86-kilodalton immediate-early 2 protein: synthesis as a precursor polypeptide and interaction with a 75-kilodalton protein of probable viral origin. 1994 Feb. J Virol. 68(2):720-9. National Cancer Institute National Center for Research Resources Fu TM. Bonneau RH. Tevethia MJ. Tevethia SS. Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes. 1993 Nov. J Virol. 67(11):6866-71. National Cancer Institute Kierstead TD. Tevethia MJ. Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. 1993 Apr. J Virol. 67(4):1817-29. National Cancer Institute Lill NL. Tevethia MJ. Hendrickson WG. Tevethia SS. Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes. 1992 Aug 1. J Exp Med. 176(2):449-57. National Cancer Institute Deckhut AM. Tevethia MJ. Haggerty S. Frisque RJ. Tevethia SS. Localization of common cytotoxic T lymphocyte recognition epitopes on simian papovavirus SV40 and human papovavirus JC virus T antigens. 1991 Jul. Virology. 183(1):122-32. National Cancer Institute Thompson DL. Kalderon D. Smith AE. Tevethia MJ. Dissociation of Rb-binding and anchorage-independent growth from immortalization and tumorigenicity using SV40 mutants producing N-terminally truncated large T antigens. 1990 Sep. Virology. 178(1):15-34. National Cancer Institute Tevethia MJ. Pipas JM. Kierstead T. Cole C. Requirements for immortalization of primary mouse embryo fibroblasts probed with mutants bearing deletions in the 3' end of SV40 gene A. 1988 Jan. Virology. 162(1):76-89. National Cancer Institute Bates MP. Jennings SR. Tanaka Y. Tevethia MJ. Tevethia SS. Recognition of simian virus 40 T antigen synthesized during viral lytic cycle in monkey kidney cells expressing mouse H-2Kb- and H-2Db-transfected genes by SV40-specific cytotoxic T lymphocytes leads to the abrogation of virus lytic cycle. 1988 Jan. Virology. 162(1):197-205. National Institute of Allergy and Infectious Diseases National Cancer Institute Anderson RW. Tevethia MJ. Kalderon D. Smith AE. Tevethia SS. Fine mapping two distinct antigenic sites on simian virus 40 (SV40) T antigen reactive with SV40-specific cytotoxic T-cell clones by using SV40 deletion mutants. 1988 Jan. J Virol. 62(1):285-96. National Cancer Institute Tanaka Y. Tevethia MJ. Kalderon D. Smith AE. Tevethia SS. Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. 1988 Feb. Virology. 162(2):427-36. National Cancer Institute Tevethia MJ. Spector DJ. Leisure KM. Stinski MF. Participation of two human cytomegalovirus immediate early gene regions in transcriptional activation of adenovirus promoters. 1987 Dec. Virology. 161(2):276-85. National Institute of Allergy and Infectious Diseases National Cancer Institute